Both tirzepatide and retatrutide activate GIPR, but tirzepatide is strictly a dual GIP/GLP-1 agonist while retatrutide additionally activates the glucagon receptor, classifying it as a triple agonist
Importantly, the 2024 Lancet Commission on dementia specified diabetes and obesity as modifiable factors that raise the risk of disease by approximately 70% and 30%, respectively, Lin and colleagues point out
Additionally, some preliminary studies have revealed a connection between H
Why Oxidative Stress Increases During GLP-1 Weight Loss Tirzepatide works by activating both GIP and GLP-1 receptors in the hypothalamus and pancreas, reducing appetite signaling while improving insulin sensitivity
However, because retatrutide's full pharmacological profile is still under investigation, all supplements should be disclosed to a healthcare professional for an individualised risk assessment